Exacerbation of diabetic renal alterations in mice lacking vasohibin-1

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Hinamoto, Norikazu ^a   Maeshima, Yohei ^a   Yamasaki, Hiroko ^a   Nasu, Tatsuyo ^a   Saito, Daisuke ^a   Watatani, Hiroyuki ^a   Ujike, Haruyo ^a   Tanabe, Katsuyuki ^a   Masuda, Kana ^a   Arata, Yuka ^a   Sugiyama, Hitoshi ^a   Sato, Yasufumi ^b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS MODULATOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ARGINASE 1; CD31 ANTIGEN; CD34 ANTIGEN; CELL PROTEIN; COLLAGEN TYPE 4; CREATININE; HEMOGLOBIN A1C; I KAPPA B ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PROTEIN ZO1; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASOHIBIN 1; CELL CYCLE PROTEIN; VASOHIBIN PROTEIN, MOUSE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL DAMAGE; CELL INFILTRATION; CELL PROTECTION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; GENETIC TRANSFECTION; GLOMERULAR SLIT DIAPHRAGM DENSITY; GLOMERULUS BASEMENT MEMBRANE; HETEROZYGOTE; IMMORTALIZED CELL LINE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY HYPERTROPHY; KNOCKOUT MOUSE; MALE; MONOCYTE; MOUSE; NEPHRITIS; NONHUMAN; PODOCYTE; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RENAL PROTECTION; RENAL SYSTEM PARAMETERS; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; URINARY EXCRETION; WILD TYPE; ANIMAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; ENDOTHELIUM CELL; GENE INACTIVATION; GENETICS; GLOMERULUS; HYPERTROPHY; METABOLISM; PATHOLOGY; URINE;

MUS;

ALBUMINURIA; ANIMALS; CELL CYCLE PROTEINS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; GENE KNOCKOUT TECHNIQUES; HETEROZYGOTE; HYPERTROPHY; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; PODOCYTES;

EID: 84907478555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107934     Document Type: Article

References (60)

1. Makino H, Kashihara N, Sugiyama H., Kanao K, Sekikawa T, et al. (1996) Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 45: 488-495.
2. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321.
3. Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146.
4. Okada S, Shikata K, Matsuda M., Ogawa D, Usui H, et al. (2003) Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593.
5. Sassy-Prigent C, Heudes D, Mandet C., Belair MF, Michel O, et al. (2000) Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49: 466-475.
6. Wang Y, Harris DC (2011) Macrophages in renal disease. J Am Soc Nephrol 22: 21-27.
7. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
8. Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55: 15-35; discussion 35-16
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
10. Guo M, Ricardo SD, Deane J.A., Shi M., Cullen-McEwen L, et al. (2005) A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 207: 813-821.
11. Nyengaard JR, Rasch R (1993) The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 36: 189-194.
12. Maeshima Y, Makino H (2010) Angiogenesis and chronic kidney disease. Fibrogenesis tissue repair 3: 13.
13. Cooper ME, Vranes D, Youssef S., Stacker SA, Cox AJ, et al. (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239.
14. Tsuchida K, Makita Z, Yamagishi S., Atsumi T, Miyoshi H, et al. (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42: 579-588.
15. de Vriese AS, Tilton RG, Elger M, Stephan C.C., Kriz W., et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000.
16. Sung SH, Ziyadeh FN, Wang A, Pyagay P.E., Kanwar YS, et al. (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17: 3093-3104.
17. Yamamoto Y, Maeshima Y, Kitayama H., Kitamura S, Takazawa Y, et al. (2004) Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840.
18. Ichinose K, Maeshima Y, Yamamoto Y., Kitayama H, Takazawa Y, et al. (2005) Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54: 2891-2903.
19. Watanabe K, Hasegawa Y, Yamashita H., Shimizu K, Ding Y, et al. (2004) Vasohibin as an endothelium-derived negative feedback regulator of angiogen-esis. J Clin Invest 114: 898-907.
20. Miyashita H, Watanabe T, Hayashi H., Suzuki Y, Nakamura T, et al. (2012) Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PLoS One 7: e46459.
21. Yamashita H, Abe M, Watanabe K., Shimizu K, Moriya T, et al. (2006) Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Commun 345: 919-925.
22. Hosaka T, Kimura H, Heishi T., Suzuki Y, Miyashita H, et al. (2009) Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol 175: 430-439.
23. Li D, Zhou K, Wang S., Shi Z, Yang Z (2010) Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Sci 101: 448-452.
24. Heishi T, Hosaka T, Suzuki Y., Miyashita H, Oike Y, et al. (2010) Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol 176: 1950-1958.
25. Nasu T, Maeshima Y, Kinomura M., Hirokoshi-Kawahara K, Tanabe K, et al. (2009) Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58: 2365-2375.
26. Saito D, Maeshima Y, Nasu T., Yamasaki H, Tanabe K, et al. (2011) Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 300: F873-886.
27. Kimura H, Miyashita H, Suzuki Y., Kobayashi M, Watanabe K, et al. (2009) Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 113: 4810-4818.
28. Hashimoto N, Maeshima Y, Satoh M., Odawara M, Sugiyama H, et al. (2004) Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 286: F516-525.
29. Ichinose K, Maeshima Y, Yamamoto Y., Kinomura M, Hirokoshi K, et al. (2006) 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 55: 1232-1242.
30. Kuwabara T, Mori K, Mukoyama M., Kasahara M, Yokoi H, et al. (2012) Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Tolllike receptor 4 in mice. Diabetologia 55: 2256-2266.
31. Veron D, Reidy KJ, Bertuccio C, Teichman J., Villegas G, et al. (2010) Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 77: 989-999.
32. Shen J, Yang X, Xiao W.H., Hackett SF, Sato Y, et al. (2006) Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J 20: 723-725.
33. Fiedler U, Reiss Y, Scharpfenecker M., Grunow V, Koidl S, et al. (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235-239.
34. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364: 656-665.
35. Takano Y, Yamauchi K, Hiramatsu N., Kasai A, Hayakawa K, et al. (2007) Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol 292: F1573-1582.
36. Breyer MD, Bottinger E, Brosius FC III, Coffman TM, Harris RC, et al. (2005) Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45.
37. Zent R, Pozzi A (2006) Antiangiogenic therapy in diabetic nephropathy. J Am Soc Nephrol 17: 325-327.
38. Benzing T (2004) Signaling at the slit diaphragm. J Am Soc Nephrol 15: 1382-1391.
39. Hohenstein B, Hausknecht B, Boehmer K., Riess R, Brekken RA, et al. (2006) Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69: 1654-1661.
40. Hovind P, Tarnow L, Oestergaard P.B., Parving HH (2000) Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 75: S56-61.
41. Sivaskandarajah GA, Jeansson M, Maezawa Y., Eremina V, Baelde HJ, et al. (2012) Vegfa protects the glomerular microvasculature in diabetes. Diabetes 61: 2958-2966.
42. Satchell SC, Harper SJ, Tooke J.E., Kerjaschki D., Saleem MA, et al. (2002) Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 13: 544-550.
43. Woolf AS, Gnudi L, Long DA (2009) Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 20: 239-244.
44. Sato W, Kosugi T, Zhang L., Roncal CA, Heinig M, et al. (2008) The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab invest 88: 949-961.
45. Anders HJ, Ryu M (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925.
46. Ricardo SD, van Goor H, Eddy AA (2008) Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522-3530.
47. Herbert DR, Holscher C, Mohrs M., Arendse B, Schwegmann A, et al. (2004) Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20: 623-635.
48. Pull SL, Doherty JM, Mills J.C., Gordon JI, Stappenbeck TS (2005) Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A 102: 99-104.
49. Wang W, Koka V, Lan HY (2005) Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology 10: 48-56.
50. Lan HY (2011) Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 7: 1056-1067.
51. Verrecchia F, Chu ML, Mauviel A (2001) Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276: 17058-17062.
52. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, et al. (2005) Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 20: 1320-1328.
53. Hinamoto N, Maeshima Y, Saito D., Yamasaki H, Tanabe K, et al. (2014) Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders. PLoS One 9: e96932.
54. Miyazaki Y, Kosaka T, Mikami S., Kikuchi E, Tanaka N, et al. (2012) The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res 18: 4145-4153.
55. Wang Q, Tian X, Zhang C (2012) Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol 29: 2727-2736.
56. Yoshinaga K, Ito K, Moriya T., Nagase S, Takano T, et al. (2008) Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci 99: 914-919.
57. Tamaki K, Moriya T, Sato Y., Ishida T, Maruo Y, et al. (2009) Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogen-esis. Cancer Sci 100: 88-94.
58. Tamaki K, Sasano H, Maruo Y., Takahashi Y, Miyashita M, et al. (2010) Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci 101: 1051-1058.
59. Yoshinaga K, Ito K, Moriya T., Nagase S, Takano T, et al. (2011) Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer Sci 102: 446-451.
60. Watanabe T, Okada Y, Hoshikawa Y., Eba S, Notsuda H, et al. (2012) A potent anti-angiogenic factor, vasohibin-1, ameliorates experimental bronchiolitis obliterans. Transplant Proc 44: 1155-1157.